Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study.

Although the PFS and the OS were prolonged compared with those achieved with Rd in the subset of patients who did not receive an ASCT, the OS benefit did not reach statistical significance in patients aged 65 years or older.

also in 111,027 other papers